Molecular Partners AG
MP0712
small cell lung cancer
Countdown
542days
Phase 3 readout · ~ Dec 31, 2027 estimated
What's at stake
Phase 3 trial results for MP0712 in small cell lung cancer are due ~ Dec 31, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 13h ago
“comprehensive efficacy data expected in 2027”